A Roche of la Grippe: India’s Natco and Alvogen launch Tamiflu generic in US

By Dani Bancroft contact

- Last updated on GMT

Image: Natco Pharma
Image: Natco Pharma

Related tags: Oseltamivir, Influenza

Natco Pharma and partner Alvogen have launched the “first generic equivalent” of Roche’s Tamiflu (oseltamivir phosphate) in the US.

The US FDA approved India based Natco Pharma and its US partner Alvogen’s application for a generic of Tamiflu in August.

Alvogen—a CMO with more than 350 generic products on the market—told Reuters​ it expected “the cheaper product to save the US healthcare system over $500M in the upcoming flu season.”

Tamiflu has previously faced criticism after a 2014 Cochrane review​ reported little evidence of the drug’s efficacy in reducing viral spread, the number of complications and hospitalisations of patients with influenza.

Patents

Oseltamivir phosphate is an oral neuraminidase inhibitor invented by Gilead Science Inc., licensed out to Roche as Tamiflu in 1996.

In 2011, Natco first challenged​ Gilead’s patent of Tamiflu, over claims it was invalid. A settlement was made last December, with Natco proceeding to go ahead with development of its 30mg, 50mg and 75mg of oseltamivir phosphate capsules.

But Natco and Alvogen are not alone in their pursuit of a Tamiflu generic.

Cipla Ltd. marketed Antiflu back in 2011, which contains the same API as Tamiflu—oseltamivir phosphate—in a capsule and syrup formulation.

Roche granted Hetero Drugs​ in India a sublicense to manufacture oseltamivir in 2006.

Natco and Alvogen did not respond to requests for further information.

Related news

Show more

Related products

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars